<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2021.116401</article-id><article-id pub-id-type="publisher-id">ACM-43330</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20210600000_92307773.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  胸腺法新用于治疗新型冠状病毒肺炎重症和危重症患者的疗效和安全性研究
  Study on the Efficacy and Safety of Thymalfasin for Treatment of Critically Novel Coronavirus Pneumonia Patients
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>冉</surname><given-names>启惠</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>陈</surname><given-names>红</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>张</surname><given-names>玲</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>成都市公共卫生临床医疗中心重症医学科，四川 成都</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>01</day><month>06</month><year>2021</year></pub-date><volume>11</volume><issue>06</issue><fpage>2768</fpage><lpage>2775</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  目的：评价胸腺法新用于治疗新型冠状病毒肺炎重症和危重症患者的疗效和安全性。方法：计划纳入30名新型冠状病毒肺炎重症和危重症患者，随机分配到试验组和对照组各15例。对照组执行国家卫健委发布的最新新型冠状病毒肺炎诊疗方案(简称“诊疗方案”)，试验组在执行诊疗方案的基础上，皮下注射胸腺法新1.6 mg/次，连续7天。比较治疗过程第1、3、7、14天及治愈出院后28天两组患者的细胞免疫学指标变化情况和不良事件发生率。结果：两组患者CD3+、CD4+、CD8+计数和CD4+/CD8+水平同期比较差异无统计学意义(P &gt; 0.05)；免疫治疗组CD3+、CD4+、CD8+计数第7、14和治愈出院后第28天与基线比较差异有统计学意义(P &lt; 0.05)；治疗过程中两组患者CD3+、CD4+、CD8+计数及指标处于正常范围的患者例数均有所增加，免疫治疗组的增加幅度大于常规治疗组(P &lt; 0.05)；主要疗效指标和不良事件发生率两组比较差异无统计学意义(P &gt; 0.05)。结论：本研究提示胸腺法新可能小幅提升细胞免疫抑制状态的新型冠状病毒肺炎重症和危重症患者的CD3+、CD4+、CD8+T淋巴细胞计数，没有足够证据显示其能够改善该类患者的预后。
   Objective: To evaluate the efficacy and safety of thymalfasin in the treatment of COVID-19 patients with severe and critical diseases. Methods: Thirty patients with severe and critical COVID-19 were enrolled and randomly assigned to the experimental group and the control group with 15 patients in each group. The control group was given the latest COVID-19 Diagnosis and Treatment Scheme (referred to as “Diagnosis and Treatment Scheme”) issued by the National Health Commission, while the experimental group was given subcutaneous injection of 1.6 mg/time for 7 consecutive days on the basis of the Diagnosis and Treatment Scheme. The changes of cellular immunological indexes and the incidence of adverse events were compared between the two groups on day 1, 3, 7, 14 of the treatment process and 28 days after discharge. Results: There was no significant difference in CD3+, CD4+, CD8+ count and CD4+/CD8+ level between 2 groups (P &gt; 0.05). There were significant differences in CD3+, CD4+, CD8+ counts between the immunotherapy group and the baseline at the 7th, 14th day and the 28th day after discharge (P &lt; 0.05). During treatment, the number of patients with CD3+, CD4+, CD8+ counts and indexes in the normal range increased in both groups, and the increase rate in the immunotherapy group was greater than that in the conventional treatment group (P &lt; 0.05). There was no significant difference in the main efficacy indexes and the incidence of adverse events between the two groups (P &gt; 0.05). Conclusion: The study suggested that thymalfasin may slightly increase the CD3+, CD4+, and CD8+T lymphocyte count in critical COVID-19 patients with cellular immunosuppression, but there is not enough evidence to show that it can improve the prognosis of these patients.
 
</p></abstract><kwd-group><kwd>新型冠状病毒肺炎，免疫调节，胸腺法新，细胞免疫, COVID-19</kwd><kwd> Immune Regulation</kwd><kwd> Thymalfasin</kwd><kwd> Cellular Immune</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>摘要</title><p>目的：评价胸腺法新用于治疗新型冠状病毒肺炎重症和危重症患者的疗效和安全性。方法：计划纳入30名新型冠状病毒肺炎重症和危重症患者，随机分配到试验组和对照组各15例。对照组执行国家卫健委发布的最新新型冠状病毒肺炎诊疗方案(简称“诊疗方案”)，试验组在执行诊疗方案的基础上，皮下注射胸腺法新1.6 mg/次，连续7天。比较治疗过程第1、3、7、14天及治愈出院后28天两组患者的细胞免疫学指标变化情况和不良事件发生率。结果：两组患者CD3+、CD4+、CD8+计数和CD4+/CD8+水平同期比较差异无统计学意义(P &gt; 0.05)；免疫治疗组CD3+、CD4+、CD8+计数第7、14和治愈出院后第28天与基线比较差异有统计学意义(P &lt; 0.05)；治疗过程中两组患者CD3+、CD4+、CD8+计数及指标处于正常范围的患者例数均有所增加，免疫治疗组的增加幅度大于常规治疗组(P &lt; 0.05)；主要疗效指标和不良事件发生率两组比较差异无统计学意义(P &gt; 0.05)。结论：本研究提示胸腺法新可能小幅提升细胞免疫抑制状态的新型冠状病毒肺炎重症和危重症患者的CD3+、CD4+、CD8+T淋巴细胞计数，没有足够证据显示其能够改善该类患者的预后。</p></sec><sec id="s2"><title>关键词</title><p>新型冠状病毒肺炎，免疫调节，胸腺法新，细胞免疫</p></sec><sec id="s3"><title>Study on the Efficacy and Safety of Thymalfasin for Treatment of Critically Novel Coronavirus Pneumonia Patients<sup> </sup></title><p>Qihui Ran, Hong Chen, Ling Zhang</p><p>Department of Critical Care Medicine, The Public Health Clinical Center of Chengdu, Chengdu Sichuan</p><p><img src="//html.hanspub.org/file/43-1572303x4_hanspub.png" /></p><p>Received: May 17<sup>th</sup>, 2021; accepted: Jun. 3<sup>rd</sup>, 2021; published: Jun. 23<sup>rd</sup>, 2021</p><p><img src="//html.hanspub.org/file/43-1572303x5_hanspub.png" /></p></sec><sec id="s4"><title>ABSTRACT</title><p>Objective: To evaluate the efficacy and safety of thymalfasin in the treatment of COVID-19 patients with severe and critical diseases. Methods: Thirty patients with severe and critical COVID-19 were enrolled and randomly assigned to the experimental group and the control group with 15 patients in each group. The control group was given the latest COVID-19 Diagnosis and Treatment Scheme (referred to as “Diagnosis and Treatment Scheme”) issued by the National Health Commission, while the experimental group was given subcutaneous injection of 1.6 mg/time for 7 consecutive days on the basis of the Diagnosis and Treatment Scheme. The changes of cellular immunological indexes and the incidence of adverse events were compared between the two groups on day 1, 3, 7, 14 of the treatment process and 28 days after discharge. Results: There was no significant difference in CD3+, CD4+, CD8+ count and CD4+/CD8+ level between 2 groups (P &gt; 0.05). There were significant differences in CD3+, CD4+, CD8+ counts between the immunotherapy group and the baseline at the 7th, 14th day and the 28th day after discharge (P &lt; 0.05). During treatment, the number of patients with CD3+, CD4+, CD8+ counts and indexes in the normal range increased in both groups, and the increase rate in the immunotherapy group was greater than that in the conventional treatment group (P &lt; 0.05). There was no significant difference in the main efficacy indexes and the incidence of adverse events between the two groups (P &gt; 0.05). Conclusion: The study suggested that thymalfasin may slightly increase the CD3+, CD4+, and CD8+T lymphocyte count in critical COVID-19 patients with cellular immunosuppression, but there is not enough evidence to show that it can improve the prognosis of these patients.</p><p>Keywords:COVID-19, Immune Regulation, Thymalfasin, Cellular Immune</p><disp-formula id="hanspub.43330-formula33"><graphic xlink:href="//html.hanspub.org/file/43-1572303x6_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2021 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/43-1572303x7_hanspub.png" /> <img src="//html.hanspub.org/file/43-1572303x8_hanspub.png" /></p></sec><sec id="s5"><title>1. 引言</title><p>新型冠状病毒肺炎(COVID-19，新冠肺炎)是由新型冠状病毒(SARS-CoV-2，新冠病毒)感染导致的以肺炎为特征的新发传染病 [<xref ref-type="bibr" rid="hanspub.43330-ref1">1</xref>]，自2019年12月底开始流行，2020年在全球范围内大暴发 [<xref ref-type="bibr" rid="hanspub.43330-ref2">2</xref>]。截止2021-05-08，世界卫生组织(WHO)公布的相关数据显示，全球累计确诊COVID-19患者156,496,592例，死亡3,264,143例，死亡率达2.09%，并且仍不断有新发病例和死亡病例出现，严重威胁人类的健康 [<xref ref-type="bibr" rid="hanspub.43330-ref3">3</xref>]。病毒是严格的细胞内寄生的非细胞型微生物，细胞免疫系统在清除细胞内病毒感染中发挥主导作用 [<xref ref-type="bibr" rid="hanspub.43330-ref4">4</xref>]。有证据提示，有效的机体免疫应答在冠状病毒感染相关疾病的预后中发挥重要作用 [<xref ref-type="bibr" rid="hanspub.43330-ref4">4</xref>] [<xref ref-type="bibr" rid="hanspub.43330-ref5">5</xref>]。</p><p>多项研究报道，大部分新冠肺炎患者的循环T淋巴细胞低于正常值，提示免疫抑制 [<xref ref-type="bibr" rid="hanspub.43330-ref6">6</xref>] [<xref ref-type="bibr" rid="hanspub.43330-ref7">7</xref>]。从一般病毒感染个体免疫应答和药物机理的角度考虑，通过使用药物进行人工被动免疫，增强机体的细胞免疫功能，可能有助于改善新冠肺炎患者的预后。在缺少新冠肺炎特效药和治疗方案的背景下，针对细胞免疫的胸腺肽类药物引起大家的关注，但由于缺乏相关的临床试验，胸腺肽类药物治疗新冠肺炎的疗效和安全性尚不清楚。本研究针对胸腺法新在治疗新冠肺炎重症和危重症患者中的应用开展随机对照试验研究，希望能够提供真实世界的数据证据，为临床治疗新冠肺炎重症和危重症患者提供参考。</p></sec><sec id="s6"><title>2. 资料与方法</title><sec id="s6_1"><title>2.1. 研究对象</title><p>以2020年1月至2020年5月期间收治的新型冠状病毒肺炎重型和危重型患者作为研究对象。受试对象的纳入标准为：1) 年龄 &gt; 18周岁；2) 重型患者需至少满足下列成人诊断标准中的条件之一：① 出现气促，RR ≥ 30次/分；② 静息状态下，指氧饱和度 ≤ 93%；③ 动脉血氧分压(PaO<sub>2</sub>)/吸氧浓度(FiO<sub>2</sub>) ≤ 300 mmHg (1 mmHg = 0.133 kPa)；3) 危重型患者需至少符合成人诊断标准以下情况之一：① 出现呼吸衰竭，且需要机械通气；② 出现休克；③ 合并其他器官功能衰竭需ICU监护治疗；④ 患者或监护人需对本研究知情同意并签署知情同意书。排除标准为：1) 孕妇或哺乳期妇女；2) 年龄小于18周岁；3) 对注射用胸腺法新过敏的患者；4) 正在接受免疫抑制治疗的患者；5) 接受过骨髓移植或实体器官移植的患者；6) 合并肿瘤患者；7) 获得性免疫缺陷综合征或先天免疫缺陷患者。</p></sec><sec id="s6_2"><title>2.2. 治疗方案及分组</title><p>计划纳入30例新型冠状病毒肺炎重症和危重症患者，先按病情严重程度分为重症和危重症两层，再根据患者的年龄、合并疾病、免疫水平区组随机分配到试验组和对照组各15例。对照组(常规治疗组)遵循试验期间国家卫健委发布的最新新型冠状病毒肺炎诊疗方案(简称“诊疗方案”)治疗，试验组(免疫治疗组)在执行诊疗方案的基础上，皮下注射胸腺法新1.6 mg/次，一天一次，连续7天。</p></sec><sec id="s6_3"><title>2.3. 观察指标</title><p>于治疗前及治疗第1、3、7、14和患者治愈出院后第28天监测记录患者的CD3+、CD4+、CD8+T淋巴细胞计数和CD4+/CD8+水平。治疗过程中监测可能发生的临床不良事件。于治疗前后观察2组的生命体征、血常规、器官功能受损情况。</p></sec><sec id="s6_4"><title>2.4. 伦理学</title><p>本研究符合医学伦理学标准，并经过成都市公共卫生临床医疗中心伦理委员会的审批(审批号：PJ-K2020-12-01)，所有治疗及检测均获得过患者或家属的知情同意。</p></sec><sec id="s6_5"><title>2.5. 统计学方法</title><p>用Microsoft Excel软件收集和整理入组患者的临床数据，建立病例资料数据库，采用SPSS25.0统计软件对数据进行统计分析。正态分布的计量资料以均数&#177;标准差( x &#175; &#177; s )表示，组间比较用t检验或单因素方差分析；非正态分布的计量资料以中位数(四分位数) [M(QL, QU)]表示，组间比较用秩和检验(Mann-Whitney U)；计数资料以例或率(%)表示，组间比较用c2检验。P &lt; 0.05为差异有统计学意义。</p></sec></sec><sec id="s7"><title>3. 结果</title><sec id="s7_1"><title>3.1. 基线资料比较</title><p>本研究最终纳入30例受试患者，试验组和对照组各15例；两组患者人口学资料(性别、年龄)、一般临床资料(病史情况、合并疾病、病情严重程度)、进入重症24小时内的疗效相关主要实验室检查指标(CD3+、CD4+和CD8+T淋巴细胞计数等)比较差异均无统计学意义(P &gt; 0.05)，具有可比性，详见表1。</p><table-wrap-group id="1"><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> Comparison of baseline data between control group and experimental grou</title></caption><table-wrap id="1_1"><table><tbody><thead><tr><th align="center" valign="middle"  rowspan="2"  >临床指标</th><th align="center" valign="middle"  colspan="2"  >分组</th><th align="center" valign="middle"  rowspan="2"  >统计量(t/Z)</th><th align="center" valign="middle"  rowspan="2"  >P值</th></tr></thead><tr><td align="center" valign="middle" >试验组(n = 15)</td><td align="center" valign="middle" >对照组(n = 15)</td></tr><tr><td align="center" valign="middle" >性别</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >男性[例(%)]</td><td align="center" valign="middle" >10 (66.7)</td><td align="center" valign="middle" >10 (66.7)</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >1.000</td></tr><tr><td align="center" valign="middle" >女性[例(%)]</td><td align="center" valign="middle" >5 (33.3)</td><td align="center" valign="middle" >5 (33.3)</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >-</td></tr><tr><td align="center" valign="middle" >年龄(岁)</td><td align="center" valign="middle" >56.9 &#177; 19.3</td><td align="center" valign="middle" >60.9 &#177; 17.9</td><td align="center" valign="middle" >−0.581</td><td align="center" valign="middle" >0.566</td></tr><tr><td align="center" valign="middle" >临床分型</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >重型患者[例(%)]</td><td align="center" valign="middle" >6 (40.0)</td><td align="center" valign="middle" >4 (26.7)</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >0.700</td></tr><tr><td align="center" valign="middle" >危重型患者[例(%)]</td><td align="center" valign="middle" >9 (60.0)</td><td align="center" valign="middle" >11 (73.3)</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >呼吸频率(次/分)</td><td align="center" valign="middle" >21 (20,23)</td><td align="center" valign="middle" >23 (22,30)</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >0.098</td></tr><tr><td align="center" valign="middle" >体温(℃)</td><td align="center" valign="middle" >37.6 &#177; 0.74</td><td align="center" valign="middle" >38.0 &#177; 0.74</td><td align="center" valign="middle" >−1.506</td><td align="center" valign="middle" >-0.143</td></tr><tr><td align="center" valign="middle" >发病症状[例(%)]</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >发热</td><td align="center" valign="middle" >14 (93.3)</td><td align="center" valign="middle" >15 (100.0)</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >1.000</td></tr><tr><td align="center" valign="middle" >咳嗽</td><td align="center" valign="middle" >12 (80.0)</td><td align="center" valign="middle" >13 (86.7)</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >1.000</td></tr><tr><td align="center" valign="middle" >气促</td><td align="center" valign="middle" >12 (80.0)</td><td align="center" valign="middle" >14 (93.3)</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >0.598</td></tr><tr><td align="center" valign="middle" >乏力</td><td align="center" valign="middle" >2 (13.3)</td><td align="center" valign="middle" >6 (40.0)</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >0.215</td></tr><tr><td align="center" valign="middle" >腹泻</td><td align="center" valign="middle" >0 (0.0)</td><td align="center" valign="middle" >1 (6.7)</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >1.000</td></tr><tr><td align="center" valign="middle" >基础疾病[例(%)]</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >高血压</td><td align="center" valign="middle" >4 (26.7)</td><td align="center" valign="middle" >6 (40.0)</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >0.700</td></tr><tr><td align="center" valign="middle" >冠心病</td><td align="center" valign="middle" >2 (13.3)</td><td align="center" valign="middle" >3 (20.0)</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >1.000</td></tr><tr><td align="center" valign="middle" >糖尿病</td><td align="center" valign="middle" >4 (26.7)</td><td align="center" valign="middle" >3 (20.0)</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >1.000</td></tr><tr><td align="center" valign="middle" >慢性肾衰竭</td><td align="center" valign="middle" >1 (6.7)</td><td align="center" valign="middle" >3 (20.0)</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >0.598</td></tr><tr><td align="center" valign="middle" >器官功能损伤[例(%)]</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >休克</td><td align="center" valign="middle" >3 (20.0)</td><td align="center" valign="middle" >5 (33.3)</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >0.682</td></tr><tr><td align="center" valign="middle" >心肌损害</td><td align="center" valign="middle" >4 (26.7)</td><td align="center" valign="middle" >7 (46.7)</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >0.450</td></tr><tr><td align="center" valign="middle" >肝功损害</td><td align="center" valign="middle" >8 (53.3)</td><td align="center" valign="middle" >7 (46.7)</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >0.715</td></tr><tr><td align="center" valign="middle" >细胞免疫缺陷</td><td align="center" valign="middle" >14 (93.3)</td><td align="center" valign="middle" >13 (86.7)</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >1.000</td></tr><tr><td align="center" valign="middle" >病情评分</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >SOFA评分(分)</td><td align="center" valign="middle" >2.93 &#177; 1.39</td><td align="center" valign="middle" >4.47 &#177; 3.34</td><td align="center" valign="middle" >−1.644</td><td align="center" valign="middle" >0.111</td></tr><tr><td align="center" valign="middle" >APACHE II评分(分)</td><td align="center" valign="middle" >9.87 &#177; 4.51</td><td align="center" valign="middle" >13.13 &#177; 5.43</td><td align="center" valign="middle" >−1.790</td><td align="center" valign="middle" >0.084</td></tr><tr><td align="center" valign="middle" >实验室检查指标</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >氧合指数(mmhg)</td><td align="center" valign="middle" >215.2 &#177; 74.7</td><td align="center" valign="middle" >243.5 &#177; 66.1</td><td align="center" valign="middle" >−1.089</td><td align="center" valign="middle" >0.285</td></tr><tr><td align="center" valign="middle" >中性粒细胞率(%)</td><td align="center" valign="middle" >78.11 &#177; 7.89</td><td align="center" valign="middle" >79.41 &#177; 10.43</td><td align="center" valign="middle" >−0.385</td><td align="center" valign="middle" >0.703</td></tr><tr><td align="center" valign="middle" >淋巴细胞计数(&#215;10<sup>9</sup>/L)</td><td align="center" valign="middle" >0.85 &#177; 0.37</td><td align="center" valign="middle" >0.88 &#177; 0.59</td><td align="center" valign="middle" >−0.182</td><td align="center" valign="middle" >0.857</td></tr><tr><td align="center" valign="middle" >C-反应蛋白(mg/L)</td><td align="center" valign="middle" >29.95 &#177; 7.30</td><td align="center" valign="middle" >67.03 &#177; 40.63</td><td align="center" valign="middle" >−2.901</td><td align="center" valign="middle" >0.007</td></tr></tbody></table></table-wrap><table-wrap id="1_2"><table><tbody><thead><tr><th align="center" valign="middle" >CD3+细胞计数(cells/μl)</th><th align="center" valign="middle" >471.40 &#177; 238.81</th><th align="center" valign="middle" >509.60 &#177; 331.11</th><th align="center" valign="middle" >−0.362</th><th align="center" valign="middle" >0.720</th></tr></thead><tr><td align="center" valign="middle" >CD4+/CD8+(</td><td align="center" valign="middle" >1.72 &#177; 1.22</td><td align="center" valign="middle" >1.48 &#177; 0.62</td><td align="center" valign="middle" >−0.685</td><td align="center" valign="middle" >0.499</td></tr><tr><td align="center" valign="middle" >降钙素原(ng/Ml)</td><td align="center" valign="middle" >0.07 &#177; 0.13</td><td align="center" valign="middle" >0.11 &#177; 0.20</td><td align="center" valign="middle" >−0.552</td><td align="center" valign="middle" >0.585</td></tr><tr><td align="center" valign="middle" >血清铁蛋白(ng/mL)</td><td align="center" valign="middle" >484.03 &#177; 356.05</td><td align="center" valign="middle" >376.07 &#177; 147.17</td><td align="center" valign="middle" >1.020</td><td align="center" valign="middle" >0.323</td></tr><tr><td align="center" valign="middle" >白细胞计数(&#215;10<sup>9</sup>cells/L)</td><td align="center" valign="middle" >5.98 (4.33,9.46)</td><td align="center" valign="middle" >6.15 (4.08,8.52)</td><td align="center" valign="middle" >0.104</td><td align="center" valign="middle" >0.917</td></tr><tr><td align="center" valign="middle" >CD4+细胞计数(cells/μl)</td><td align="center" valign="middle" >264.0 &#177; 165.0</td><td align="center" valign="middle" >254.5 &#177; 151.1</td><td align="center" valign="middle" >0.165</td><td align="center" valign="middle" >0.870</td></tr><tr><td align="center" valign="middle" >CD8+细胞计数(cells/μl)</td><td align="center" valign="middle" >175.5 &#177; 104.8</td><td align="center" valign="middle" >221.1 &#177; 180.8</td><td align="center" valign="middle" >−0.844</td><td align="center" valign="middle" >0.408</td></tr><tr><td align="center" valign="middle" >空腹血糖(mmol/L)</td><td align="center" valign="middle" >8.59 (5.71,14.06)</td><td align="center" valign="middle" >6.29 (5.70,9.56)</td><td align="center" valign="middle" >−1.141</td><td align="center" valign="middle" >0.254</td></tr><tr><td align="center" valign="middle" >D-二聚体(μg/ml)</td><td align="center" valign="middle" >0.83 (0.59,1.52)</td><td align="center" valign="middle" >1.28 (1.10,1.90)</td><td align="center" valign="middle" >−2.219</td><td align="center" valign="middle" >0.026</td></tr></tbody></table></table-wrap></table-wrap-group><p>表1. 对照组和试验组患者基线资料比较</p></sec><sec id="s7_2"><title>3.2. 两组患者免疫指标同期比较</title><p>两组患者治疗第1、3、7、14及出院后28天，CD3+、CD4+、CD8+T淋巴细胞计数、CD4+/CD8+水平同期比较，差异无统计学意义(P &gt; 0.05)，两组患者不同时间点免疫指标的分布情况见图1。</p><p>图1. 对照组和试验组同期免疫指标比较</p></sec><sec id="s7_3"><title>3.3. 两组患者不同时间点免疫指标与基线比较</title><p>常规治疗组CD3+、CD4+、CD8+T淋巴细胞计数、CD4+/CD8+水平第3、7、14及出院后28天与基线比较，差异无统计学意义(P &gt; 0.05)。免疫治疗组CD3+、CD4+、CD8+T淋巴细胞计数第7、14及出院后28天与基线比较差异有统计学意义(P &lt; 0.05)，其余各组与对应基线比较差异无统计学意义(P &gt; 0.05)。</p></sec><sec id="s7_4"><title>3.4. 两组患者免疫指标随治疗时间变化情况</title><p>两组患者的免疫指标第3、7、14及出院后28天与基线相比均有不同幅度的升高，CD3+、CD4+、CD8+T淋巴细胞计数上升的最大幅度分别为免疫治疗组：481.33、277.07、235.33 (个/ul)，常规治疗组：318.17、141.77、130.80 (个/ul)，免疫治疗组的升高幅度大于常规治疗组，见图2。</p><p>两组患者CD3+、CD4+和CD8+T淋巴细胞计数处于正常范围的例数在治疗的第1和3天常规治疗组多于免疫治疗组，第7、14和患者治愈出院后28天免疫治疗组高于常规治疗组。与基线相比免疫治疗组CD3+、CD4+和CD8+检测值正常例数的最大增幅分别为8例、9例和11例，常规治疗组为2例、2例和1例，差异有统计学意义(P &lt; 0.05)，见图3。</p><p>图2. 对照组和试验组免疫指标随治疗时间的变化</p><p>图3. 2组患者不同时间点T淋巴细胞水平正常的患者例数</p></sec><sec id="s7_5"><title>3.5. 两种治疗方案的主要疗效比较</title><p>两组患者的病毒转阴时间、重症天数、肺部影像吸收时间分别为：常规治疗组16.1 &#177; 8.1天、13.1 &#177; 7.6天、10.8 &#177; 4.8天，免疫治疗组16.5 &#177; 7.6天、11.5 &#177; 4.9天、9.9 &#177; 4.0天，组间差异无统计学意义(P &gt; 0.05)。两组患者都有14例最终治愈出院，组间差异无统计学意义(P &gt; 0.05)。</p></sec><sec id="s7_6"><title>3.6. 安全性分析</title><p>两组患者治疗中及治愈出院后28天的生命体征、实验室检查指标、器官功能受损情况比较差异无统计学意义(P &gt; 0.05)。常规治疗组和免疫治疗组各报道了一例院内死亡病例，2组不良事件及不良反应发生率比较差异无统计学意义(P &gt; 0.05)。</p></sec></sec><sec id="s8"><title>4. 讨论</title><p>新型冠状病毒是一种具有包膜的正链单股RNA病毒，LU等的研究提示SARS-CoV-2的基因与SARS-CoV和MERS基因序列的同源性分别为79%和40% [<xref ref-type="bibr" rid="hanspub.43330-ref8">8</xref>] [<xref ref-type="bibr" rid="hanspub.43330-ref9">9</xref>]。SARS-CoV-2感染人体后主要引起急性呼吸系统疾病 [<xref ref-type="bibr" rid="hanspub.43330-ref10">10</xref>] [<xref ref-type="bibr" rid="hanspub.43330-ref11">11</xref>]，以发热、乏力、干咳为主要表现，重症患者多在一周出现呼吸困难，胸片呈双肺浸润性病灶，严重者快速进展为急性呼吸窘迫综合症 [<xref ref-type="bibr" rid="hanspub.43330-ref12">12</xref>] [<xref ref-type="bibr" rid="hanspub.43330-ref13">13</xref>]。多项研究证实，大多数新冠肺炎患者的循环T淋巴细胞低于正常值，且在危重症患者中淋巴细胞计数降低更加明显，提示机体细胞免疫抑制 [<xref ref-type="bibr" rid="hanspub.43330-ref14">14</xref>] [<xref ref-type="bibr" rid="hanspub.43330-ref15">15</xref>] [<xref ref-type="bibr" rid="hanspub.43330-ref16">16</xref>] [<xref ref-type="bibr" rid="hanspub.43330-ref17">17</xref>]。病毒是细胞内寄生非细胞微生物，人体的免疫系统在清除病毒过程中发挥至关重要的作用。有基于药理和既往治疗经验的研究提示，通过使用胸腺肽类免疫调节药物人工增强机体的细胞免疫功能可能会让新冠肺炎患者受益 [<xref ref-type="bibr" rid="hanspub.43330-ref18">18</xref>] [<xref ref-type="bibr" rid="hanspub.43330-ref19">19</xref>] [<xref ref-type="bibr" rid="hanspub.43330-ref20">20</xref>]。本研究以胸腺法新为免疫调节药物，在新冠肺炎重症和危重症患者中开展了随机对照试验研究。</p><p>本研究中常规治疗组和免疫治疗组患者进入重症24小时内的CD3+、CD4+和CD8+T淋巴细胞计数平均值均低于正常值的下限，组间差异无统计学意义，其中CD4+、CD8+T淋巴细胞计数水平与吴强等报道的结果一致 [<xref ref-type="bibr" rid="hanspub.43330-ref15">15</xref>]。随着患者在ICU治疗时间的增加，两组患者CD3+、CD4+和CD8+T淋巴细胞计数水平较第1天均有所增加，免疫治疗组的增加幅度大于常规治疗组，但只有免疫治疗组CD3+、CD4+、CD8+T淋巴细胞计数第7、14及出院后28天与第一天相比升高差异有统计学意义，组间同期比较差异却又不明显，提示在对新冠肺炎重症和危重症患者实施胸腺法新免疫调节剂后第7天开始CD3+、CD4+、CD8+T淋巴细胞计数较对照组有更好的改善，但改善效果有限。从疗效方面看，虽然免疫治疗组从第7天开始CD3+、CD4+、CD8+T淋巴细胞恢复正常患者数量多于常规治疗组，两组患者的病毒转阴时间、重症天数、肺部影像吸收时间比较差异无统计学意义，在胡家光等报道的一项研究中也得出了相似的结果 [<xref ref-type="bibr" rid="hanspub.43330-ref21">21</xref>]，提示皮下注射胸腺法新1.6 mg/次，一天一次，连续7天，可能会在有限的小范围内增强患者的细胞免疫功能，但不足以改善新冠肺炎重症和危重症患者的预后。安全性方面，两组患者治疗中及治愈出院后28天的生命体征、实验室检查指标、器官功能受损情况比较差异无统计学意义。对照组和试验组各出现一例死亡病例，两例患者都伴有冠心病、肺部疾病、肾功能障碍等基础疾病，入院APACHE II评分和PSI评分均为高危，T淋巴细胞计数明显下降，入院后都给予积极的抗病毒、抗细菌、增强免疫治疗及有创机械通气呼吸支持，没有证据提示其死亡跟使用胸腺法新有关。</p><p>本研究存在一定的局限性，首先，这是一项单中心、小样本研究，可能会对研究结果带来一定的影响；第二是胸腺法新的使用方法和用量单一，仅评价了单一疗法的疗效；第三是随访时间短，没有对远期疗效和安全性做评估。</p></sec><sec id="s9"><title>5. 结论</title><p>综上所述，通过本研究我们发现，皮下注射胸腺法新1.6 mg/次，一天一次，连续7天，可能会对新型冠状病毒肺炎重症和危重症患者的细胞免疫功能带来更多改善，但没有证据表明胸腺法新的应用能够改善这类患者的预后。</p></sec><sec id="s10"><title>基金项目</title><p>2020年成都市科学技术局新冠肺炎防控科技项目基金(2020-YF05-00191-SN)；四川省科学技术厅项目基金(2020YFS0564)；成都市公共卫生临床医疗中心科研项目基金(K2020-02)。</p></sec><sec id="s11"><title>文章引用</title><p>冉启惠,陈 红,张 玲. 胸腺法新用于治疗新型冠状病毒肺炎重症和危重症患者的疗效和安全性研究Study on the Efficacy and Safety of Thymalfasin for Treatment of Critically Novel Coronavirus Pneumonia Patients[J]. 临床医学进展, 2021, 11(06): 2768-2775. https://doi.org/10.12677/ACM.2021.116401</p></sec><sec id="s12"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.43330-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">曹雪涛. 新型冠状病毒肺炎及新发传染病之免疫学研究[J]. 中华医学杂志, 2021, 101(1): 1-6.</mixed-citation></ref><ref id="hanspub.43330-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Wiersinga, W.J., Rhodes, A., Cheng, A.C., et al. (2020) Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A Review. JAMA, 324, 782-793. &lt;br&gt;https://doi.org/10.1001/jama.2020.12839</mixed-citation></ref><ref id="hanspub.43330-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">World Health Organization (2021) WHO Coronavirus Disease (COVID-19) Dashboard. &lt;br&gt;https://covid19.who.int</mixed-citation></ref><ref id="hanspub.43330-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Li, G., Fan, Y., Lai, Y., et al. (2020) Coronavirus Infections and Immune Responses. Journal of Medical Virology, 92, 424-432. &lt;br&gt;https://doi.org/10.1002/jmv.25685</mixed-citation></ref><ref id="hanspub.43330-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Chen, N., Zhou, M., Dong, X., et al. (2020) Epidemiological and Clinical Characteristics of 99 Cases of 2019 Novel Coronavirus Pneumonia in Wuhan, China: A Descriptive Study. The Lancet, 395, 507-513.  
&lt;br&gt;https://doi.org/10.1016/S0140-6736(20)30211-7</mixed-citation></ref><ref id="hanspub.43330-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">卢子龙, 何如愿, 江文洋, 等. COVID-19患者临床特征及免疫功能分析[J]. 武汉大学学报(医学版), 2020, 41(4): 529-532, 546.</mixed-citation></ref><ref id="hanspub.43330-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">蒋红梅, 陈竹, 曾义岚, 陈红, 张玲, 曾明全, 冉启惠, 张丽慧, 邓超, 杜清, 赵玄. 四川省30例重症新型冠状病毒肺炎的临床特征分析[J]. 四川医学, 2020, 41(6): 561-565.</mixed-citation></ref><ref id="hanspub.43330-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Lu, R., Zhao, X., Li, J., et al. (2020) Genomic Characterisation and Epidemiology of 2019 Novel Coronavirus: Implications for Virus Origins and Receptor Binding. The Lancet, 395, 565-574.  
&lt;br&gt;https://doi.org/10.1016/S0140-6736(20)30251-8</mixed-citation></ref><ref id="hanspub.43330-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Chan, J.F., Kok, K.H., Zhu, Z., et al. (2020) Genomic Characterization of the 2019 Novel Human-Pathogenic Coronavirus Isolated from a Patient with Atypical Pneumonia after Visiting Wuhan. Emerging Microbes &amp; Infections, 9, 221-236. &lt;br&gt;https://doi.org/10.1080/22221751.2020.1719902</mixed-citation></ref><ref id="hanspub.43330-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Huang, C.L., Wang, Y.M., Li, X.W., et al. (2020) Clinical Features of Patients Infected with 2019 Novel Coronavirus in Wuhan, China. The Lancet, 395, 497-506. &lt;br&gt;https://doi.org/10.1016/S0140-6736(20)30183-5</mixed-citation></ref><ref id="hanspub.43330-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Zhou, P., Yang, X.L., Wang, X.G., et al. (2020) A Pneumonia Outbreak Associated with a New Coronavirus of Probable Bat Origin. Nature, 579, 270-273.</mixed-citation></ref><ref id="hanspub.43330-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">国家卫生健康委办公厅. 关于印发新型冠状病毒感染的肺炎诊疗方案(试行第五版)的通知[EB/OL]. 
http://www.nhc.gov.cn/xcs/zhengcwj/202002/3b09b894ac9b4204a79db5b8912d4440.shtml, 2020-02-05/2021-05-08.</mixed-citation></ref><ref id="hanspub.43330-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">史河水, 韩小雨, 樊艳青, 梁波, 杨帆, 韩萍, 郑传胜. 新型冠状病毒(2019-nCoV)感染的肺炎临床特征及影像学表现[J]. 临床放射学杂志, 2020, 39(1): 8-11.</mixed-citation></ref><ref id="hanspub.43330-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">全斌, 韩文正, 杨进孙, 等. 4例重型新型冠状病毒肺炎患者临床及实验室检查特点分析[J]. 皖南医学院学报, 2021, 40(1): 57-60.</mixed-citation></ref><ref id="hanspub.43330-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">吴强, 卢春晓, 肖强, 李晓龙, 江思维, 吴佳逢, 高虹. 危重型新型冠状病毒肺炎患者T淋巴细胞亚群分析[J]. 暨南大学学报(自然科学与医学版), 2021, 42(1): 80-87, 93.</mixed-citation></ref><ref id="hanspub.43330-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">孟凡萍, 郝坡. 新型冠状病毒肺炎患者外周血淋巴细胞亚群的分析研究[J]. 现代检验医学杂志, 2021, 36(2): 114-117.</mixed-citation></ref><ref id="hanspub.43330-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">王馨语, 廖静, 陈俊. 新型冠状病毒肺炎免疫学特征及免疫治疗策略的研究进展[J]. 热带医学杂志, 2020, 20(5): 571-575, 602.</mixed-citation></ref><ref id="hanspub.43330-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">蒋理添, 王昊德, 郑义, 方青, 伍丽群. 胸腺肽类药物用于预防或治疗新型冠状病毒肺炎的可能性——基于既往冠状病毒预防和治疗的总结[J]. 医学与社会, 2020, 33(5): 42-47.</mixed-citation></ref><ref id="hanspub.43330-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">刘心霞, 申平鑫, 杜姗, 杨勇, 舒永全, 边原, 童荣生, 闫峻峰, 何林, 龙恩武, 陈岷. 胸腺肽类免疫调节药物在新型冠状病毒肺炎中合理使用与药学监护[J]. 医药导报, 2020, 39(4): 451-458.</mixed-citation></ref><ref id="hanspub.43330-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">孙露, 张弨. 胸腺肽类药物在新型冠状病毒肺炎应用中的思考[J]. 临床药物治疗杂志, 2020, 18(3): 63-67.</mixed-citation></ref><ref id="hanspub.43330-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">胡家光, 蒋忠胜, 李旭, 付凯, 李敏基, 张鹏, 王晓源, 覃川. 新型冠状病毒肺炎患者16例外周血T淋巴细胞亚群的变化及意义[J]. 广东医学, 2020, 41(8): 781-783.</mixed-citation></ref></ref-list></back></article>